<DOC>
	<DOCNO>NCT01716949</DOCNO>
	<brief_summary>This trial examine feasibility , effectiveness safety combination radiotherapy ( period five week ) chemotherapy ( 5-FU Capecitabine Oxaliplatin ) 10 fraction deep regional hyperthermia patient primary locally advance locally recurrent rectal cancer . Previous pelvic irradiation case local recurrence exclude trial . The treatment protocol aim preoperatively improve tumor regression allow less aggressive surgery primary locally advanced rectal cancer high rate curative resection heavily pretreated locally recurrent rectal cancer . Primary endpoint trial feasibility rate multimodal regimen consist radiochemotherapy hyperthermia . Secondary endpoint local control , survival rate , toxicity . It plan include total number 59 patient period 2.5 year .</brief_summary>
	<brief_title>Neoadjuvant Chemoradiation With 5-FU ( Capecitabine ) Oxaliplatin Combined With Hyperthermia Rectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Rectal Neoplasms</mesh_term>
	<mesh_term>Fever</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>Age ≥ 18 year Histologically confirm , locally advanced recurrent ( recurrence tumor within less pelvis ; resectable nonresectable ) adenocarcinoma rectum ( UICC stage IIBIV ) ; distant oligometastases may present . ECOGperformance status &lt; 2 Sufficient bone marrow function : WBC &gt; 3,5 x 10^9/l Neutrophil granulocyte &gt; 1,5 x 10^9/l Platelets &gt; 100 x 10^9/l Hemoglobin &gt; 10 g/dl Sufficient liver function : Bilirubin &lt; 2,0 mg % , SGOT , SGPT , alkaline phosphatase , gGT le 3 time upper limit normal Serum creatinine &lt; 1,5 mg % , glomerular filtration rate ( comparable test ) &gt; 50 ml/min Signed studyspecific consent form prior therapy Fertile patient must use effective contraception 6 month study treatment Considered fit oxaliplatin 5FUcontaining combination chemotherapy Pelvic radiotherapy last 12 month Pregnant lactating/nursing woman Drug addiction Ontreatment participation trial Active intractable uncontrollable infection Prior concurrent malignancy ( ≤ 5 year prior enrolment study ) except rectal cancer nonmelanoma skin cancer cervical carcinoma FIGO stage 01 patient continuously diseasefree Chronic diarrhea ( &gt; NCI CTCGrad 1 ) Chronic inflammatory disease intestine Collagen vascular disease The presence congenital disease increase radiation sensitivity , example teleangiectatic ataxia , similar Preexisting uncontrolled cardiac disease , sign cardiac failure , rhythm disturbance require therapy Myocardial infarction within past 12 month Congestive heart failure Complete bundle branch block New York Heart Association ( NYHA ) class III IV heart disease Known allergic reaction study medication Cardiac pacemaker Disease would preclude chemoradiation deep regional hyperthermia Any metal implant ( exception nonclustered marker clip ) Psychological , familial , sociological , geographical condition would preclude study compliance Patients deem technically unsatisfactory deep regional hyperthermia Cardiac symptom ( &gt; NCI CTCAE Grade 1 ) due pretreatment fluoropyrimidines Neurological symptom ( &gt; NCI CTCAE Grade 1 ) due pretreatment oxaliplatin Rare hereditary problem galactose intolerance , Lapp lactase deficiency glucosegalactose malabsorption Oral anticoagulation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>rectal cancer</keyword>
	<keyword>recurrent rectal cancer</keyword>
	<keyword>hyperthermia</keyword>
	<keyword>radiation</keyword>
	<keyword>chemoradiation</keyword>
	<keyword>5-FU</keyword>
	<keyword>capecitabine</keyword>
	<keyword>oxaliplatin</keyword>
</DOC>